ENVERIC BIOSCIENCES INC (ENVB)

Company Profile

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. The company is headquartered in Naples Florida, Florida and currently employs 7 full-time employees. The company went IPO on 2009-07-21. The firm is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. The company is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The firm is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). The company has created over 1,000 novel psychedelic molecular compounds and derivatives.

Company Info

ENVERIC BIOSCIENCES INC

4851 Tamiami Trail N, Suite 200

Naples Florida FLORIDA 34103

P: 12393021707

CEO: David Johnson

Employees: 7

Website: https://www.enveric.com/